DermaPro® (CL05) is an innovative drug that is derived from dichloric acid. It is applied to poorly healing and chronic wounds by a moist wound dressing.

This wound healing therapy addresses the large unmet medical need associated with difficult to heal wounds.

Mode of action
DermaPro® carries out a dual function in supporting the body with the closure of wounds by stimulating both skin growth and disinfection.  This effective and rapid treatment includes wounds that are difficult to heal such as diabetic foot.

Clinical status – Diabetic foot ulcers

India - DermaPro received market approval

Centaur Pharmaceuticals, Mumbai, CytoTools AG’s license partner in India received market approval in October 2019 for DermaPro® ( branded as Woxheal® in India) for the treatment of diabetic foot ulcers. Thus, for the first time, the DermaTools company has obtained an approval for its new, worldwide-patented active substance molecule. With this final approval, the Indian health authorities recognize the superior performance properties of our new drug in comparison with the previous standard therapy.

The preparations for the market launch in India now commence with this marketing approval.

Europe – Dose finding completed - Phase III in preparation
The complete evaluation of the results of the European clinical dose-finding study confirmed that treatment with DermaPro® demonstrated clear superiority in comparison with controls in treatment of diabetic foot wounds. Wound treatment with DermaPro® led to complete wound closure in very significantly more cases than with control treatment.

The preparations for the application for carrying out the European phase III trials are nearing completion and selection of additional suitable countries and centers for the phase III trials has already begun and the contacts with the existing centers are being further intensified. Therefore, after receipt of the final trial approval, patient recruiting can begin promptly and quickly.

Clinical status – Venous leg ulcers

Germany - Phase II/III study must be repeated

Clinical trials with DermaPro® for the treatment of venous leg ulcers must be repeated.